>> CONTINUOUS AMR PARTNERING INITIATIVE >>

Partners AMR Insights

For its global activities AMR Insights is dependent on its highly valued partners.


Download Sponsoring Opportunities AMR Insights 2021 >>

Current partners:

Addressing the human health impacts of AMR will require building a strong and motivated coalition of like-minded health officials, clinicians, laboratorians, policymakers, patients and leaders.

NYtor (2007) designs and (co-)develops smart, molecular assays for detecting antibiotic resistance in human and veterinary diagnostics. Design and co-development take place in close collaboration with customers, selected suppliers and global partners. NYtor also produces its prototype assays.

To make a difference in the lives of people globally through our innovative medicines, vaccines, and animal health products. We are committed to being the premier, research-intensive biopharmaceutical company and are dedicated to providing leading innovations and solutions for today and the future.

BSAC is a leading influencer of antimicrobial use globally, and has been since the Society was founded in 1971.  BSAC has members across 6 continents and in 40 countries, with over 60,000 learners in 37,500 learner locations engaged in its open access e-learning programme.  BSAC publishes the Journal of Antimicrobial Chemotherapy and JAC-Antimicrobial Resistance (JAC-AMR).

ILSE is a life science technology accelerator, business incubator and a science-driven research institute that works in partnership with innovators, affiliated academic and biomedical institutions. ILSE has joined the CARB-X Global Accelerator Network as an accelerator to provide knowhow, diagnostics expertise, business strategy and other support to CARB-X’s growing portfolio of innovative antibacterial development projects.

The Global AMR R&D Hub’s Dynamic Dashboard continuously collects and presents information on more than 5.5 bn USD AMR R&D investments on human bacterial and animal infections. It also presents information on antibacterial products in the clinical development pipeline and incentives for antibiotic R&D.

What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!